<DOC>
	<DOCNO>NCT03048474</DOCNO>
	<brief_summary>This prospective , monocenter , single arm , phase II trial 33 patient unresectable MPM , experience disease progression recurrence least one previous line platinum-based systemic treatment . Nivolumab administer fix dose 240 mg every 2 week . Nivolumab give combination ipilimumab week 1 , 7 , 13 19 administer prior infusion ipilimumab . Ipilimumab administer dose 1 mg/Kg.The patient receive nivolumab monotherapy week 3 , 5 , 9 , 11 , 15 17 . From week 21 thereafter , Nivolumab administer every 2 week maximum period 1 year disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>Ipilimumab Nivolumab Treatment Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Patients undergo pre- post-treatment thoracoscopies/biopsies .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Signed informed consent form Age ≥ 18 year WHOECOG performance status 0 1 Able comply study protocol , investigator 's judgment Patients histologically confirm diagnosis recurrence MPM . Any pleural MPM subtype permit inclusion study Progressive disease least one prior systemic treatment platinumbased doublet ( cisplatin carboplatin allow ) unresectable MPM . All prior cytotoxic toxicity must resolve grade ≤ 1 prior registration Measurable disease CT scan , accord modify RECIST Criteria Mesothelioma ( Byrne MJ , 2004 ) Life expectancy ≥ 12 week Adequate hematologic organ function , define follow laboratory result , obtain within 14 day prior first study treatment : Absolute neutrophil count ( ANC ) ≥ 1500 cells/µL ( without granulocyte colonystimulating factor support within 2 week prior Cycle 1 , Day 1 ) WBC count ≥ 3000 cells/µL Lymphocyte count ≥ 250 cells/µL Platelet count ≥ 100.000/µL ( without transfusion within 2 week prior Cycle 1 , Day 1 ) Hemoglobin ≥ 5.6 mmol/L Serum albumin ≥ 25 gr/L AST , ALT alkaline phosphatase ≤ 2.5 x ULN , follow exception : patient document liver bone metastasis : alkaline phosphatase ≤ 5 x ULN Serum bilirubin ≤ 1.5 x ULN Patients know Gilbert disease serum bilirubin level ≤ 3 x ULN may enrol INR aPTT ≤ 1.5 x ULN Patients receive therapeutic anticoagulation stable dose Creatinine clearance ≥ 45 mL/min CockcroftGault , Chronic Kidney Disease Epidemiology Collaboration Modification Diet Renal Disease formula may use ; 24hour urine collection require Women postmenopausal ( ≥ 12 month nontherapy−induced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) men partner childbearing potential , must agree use adequate contraception ( double barrier birth control ) whole duration study treatment 3 month last dose therapy Women childbearing potential must negative serum urine pregnancy test within 48 hour prior first dose treatment Medical psychological impediment comply protocol Patients peritoneal MPM Prior malignancy except adequately treat basal cell squamous cell skin cancer , superficial insitu cancer bladder cancer patient diseasefree least five year Concomitant participation another clinical trial ( investigator 's judgment ) Uncontrolled pleural/peritoneal effusion , pericardial effusion ascites require recurrent drainage procedure ( monthly frequently ) Uncontrolled tumorrelated pain Patients require pain medication must stable regimen study entry . Symptomatic lesion amenable palliative radiotherapy treat prior enrolment . Previous treatment checkpoint inhibitor Pregnant lactate woman Patients brain metastasis History active autoimmune disease ( e.g . pneumonitis ; rheumatoid arthritis ; severe form psoriasis ; uncontrolled type I diabetes hypothyroidism ) History idiopathic pulmonary fibrosis ( include pneumonitis ) unresolved druginduced pneumonitis , organize pneumonia , active pneumonitis screen chest CT scan History relevant gastrointestinal disease , include , limited , Crohn 's disease , ulcerative colitis , recurrent diverticulitis Prior allogenic bone marrow transplantation prior solid organ transplantation History HIV Patients history HBV infection eligible serological profile compatible past/resolved infection ( define negative HBsAg test positive antibody HBV core antigen [ antiHBc ] antibody test ) HBsAg test HBVDNA negative prior Cycle 1 , Day 1 Patients history HCV infection must screen HCVRNA PCR test prior Cycle 1 , Day 1 , eligible test turn negative Other serious concomitant disease , include : Active tuberculosis Severe infection within 4 week prior Cycle 1 , Day 1 Significant cardiovascular disease ( NYHA class III IV ) , myocardial infarction within previous 6 month , unstable angina , unstable arrhythmia Significant pulmonary ( asthma COPD ) hepatic disease illness consider investigator constitute unwarranted high risk investigational treatment Major surgical procedure within 28 day prior Cycle 1 , Day 1 Concurrent medication Treatment systemic immunosuppressive medication , include limited prednisone ( specific exception ; see ) , cyclophosphamide , azathioprine , methotrexate , thalidomide , anti−tumor necrosis factor [ antiTNF ] agent ) within 2 week prior Cycle 1 , Day 1 . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) allow . The use systemic prednisone dosage 10 mg/day low ( equivalent ) allow . • Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>progressive disease least 1 course chemotherapy</keyword>
</DOC>